135 related articles for article (PubMed ID: 3125989)
1. In vivo generation of lymphokine-activated killer cells by sensitization with interleukin 2-producing syngeneic T-lymphoma cells.
Nishimura T; Uchiyama Y; Hashimoto Y
Cell Immunol; 1988 Mar; 112(1):220-5. PubMed ID: 3125989
[TBL] [Abstract][Full Text] [Related]
2. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
4. Recombinant interleukin 2 allows the differentiation of Thy 1.2+ LAK cells from nude mouse spleen cells.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Immunol Lett; 1986 Mar; 12(2-3):77-82. PubMed ID: 2873098
[TBL] [Abstract][Full Text] [Related]
5. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin 2 on fetal thymocytes in organ cultures: generation of lymphokine-activated killer cells.
Skinner M; Marbrook J
Cell Immunol; 1988 Mar; 112(1):104-11. PubMed ID: 3125986
[TBL] [Abstract][Full Text] [Related]
7. Induction of nonspecific killer T cells from non-immune mouse spleen cells by culture with interleukin 2.
Nishimura T; Hashimoto Y
Gan; 1984 Feb; 75(2):177-86. PubMed ID: 6203806
[TBL] [Abstract][Full Text] [Related]
8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
9. Autocytotoxic activity of lymphokine-activated killer cells: characterization of effector cells and susceptible targets.
Suzuki H; Ikemoto M; Kamitani T; Hoshino K; Yano S
Anticancer Res; 1989; 9(2):293-7. PubMed ID: 2568770
[TBL] [Abstract][Full Text] [Related]
10. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
Cell Immunol; 1986 Jun; 100(1):149-57. PubMed ID: 2874890
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
Nishimura T; Burakoff SJ; Herrmann SH
J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
Yun YS; Hargrove ME; Ting CC
J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.
Mulé JJ; Smith CA; Rosenberg SA
J Exp Med; 1987 Sep; 166(3):792-7. PubMed ID: 3498002
[TBL] [Abstract][Full Text] [Related]
18. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity.
Aoki T; Kikuchi H; Miyatake S; Oda Y; Iwasaki K; Yamasaki T; Kinashi T; Honjo T
J Exp Med; 1989 Aug; 170(2):583-8. PubMed ID: 2787831
[TBL] [Abstract][Full Text] [Related]
20. Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells.
Merluzzi VJ; Smith MD; Last-Barney K
Cell Immunol; 1986 Jul; 100(2):563-9. PubMed ID: 3489533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
